Research
Hormonal
Semaglutide reduces the composite of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke by 20% in adults with established cardiovascular disease.
GLP-1 therapies may also provide cardiovascular benefits, which is important for patient management.
StrongSupportsmedium confidence
semaglutide reduced the composite of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke by 20%.
Why this rating
Based on the SELECT trial with a large sample size.
Source
Reframing obesity as a chronic, multifactorial disease: Clinical implications of GLP-1–based therapies
Roopesh Jain · Advances in Biomedical and Health Sciences · 2026
review · n=17604
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →